245 related articles for article (PubMed ID: 28726232)
1. [Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide].
Garcia-Estevez DA; Pardo-Parrado M; Silvarrey-Rodriguez S
Rev Neurol; 2017 Aug; 65(4):153-156. PubMed ID: 28726232
[TBL] [Abstract][Full Text] [Related]
2. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
Cernuda-Morollón E; Larrosa D; Ramón C; Vega J; Martínez-Camblor P; Pascual J
Neurology; 2013 Oct; 81(14):1191-6. PubMed ID: 23975872
[TBL] [Abstract][Full Text] [Related]
3. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial.
Mohammadianinejad SE; Abbasi V; Sajedi SA; Majdinasab N; Abdollahi F; Hajmanouchehri R; Faraji A
Clin Neuropharmacol; 2011; 34(4):174-7. PubMed ID: 21738025
[TBL] [Abstract][Full Text] [Related]
4. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
Pérez-Pereda S; Toriello-Suárez M; Ocejo-Vinyals G; Guiral-Foz S; Castillo-Obeso J; Montes-Gómez S; Martínez-Nieto RM; Iglesias F; González-Quintanilla V; Oterino A
Mol Biol Rep; 2020 Sep; 47(9):7125-7138. PubMed ID: 32951099
[TBL] [Abstract][Full Text] [Related]
5. The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial.
Ghorbani Z; Rafiee P; Fotouhi A; Haghighi S; Rasekh Magham R; Ahmadi ZS; Djalali M; Zareei M; Razeghi Jahromi S; Shahemi S; Mahmoudi M; Togha M
J Headache Pain; 2020 Feb; 21(1):22. PubMed ID: 32093657
[TBL] [Abstract][Full Text] [Related]
6. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
7. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
[TBL] [Abstract][Full Text] [Related]
8. [Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate].
Pascual-Gómez J; Alañá-García M; Oterino A; Leira R; Láinez-Andrés JM
Rev Neurol; 2008 Nov 1-15; 47(9):449-51. PubMed ID: 18985592
[TBL] [Abstract][Full Text] [Related]
9. The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial.
Elgamal S; Ahmed SR; Nahas MM; Hendawy SR; Elshafei O; Zeinhom MG
Acta Neurol Belg; 2024 Jun; 124(3):965-972. PubMed ID: 38502425
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal.
Lee MJ; Lee SY; Cho S; Kang ES; Chung CS
J Headache Pain; 2018 Jul; 19(1):53. PubMed ID: 30006780
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls.
Kamm K; Straube A; Ruscheweyh R
Cephalalgia; 2019 Oct; 39(12):1535-1543. PubMed ID: 31603037
[TBL] [Abstract][Full Text] [Related]
12. Zonisamide for migraine prophylaxis in patients refractory to topiramate.
Bermejo PE; Dorado R
Clin Neuropharmacol; 2009; 32(2):103-6. PubMed ID: 18978487
[TBL] [Abstract][Full Text] [Related]
13. Interictal amylin levels in chronic migraine patients: A case-control study.
Irimia P; Martínez-Valbuena I; Mínguez-Olaondo A; Domínguez-Vivero C; Sánchez-Arias JA; Martínez-Vila E; Luquin MR; Leira R
Cephalalgia; 2021 Apr; 41(5):604-612. PubMed ID: 33269952
[TBL] [Abstract][Full Text] [Related]
14. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study.
Villani V; Ciuffoli A; Prosperini L; Sette G
Headache; 2011 Feb; 51(2):287-91. PubMed ID: 21284610
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally.
Gallai V; Sarchielli P; Floridi A; Franceschini M; Codini M; Glioti G; Trequattrini A; Palumbo R
Cephalalgia; 1995 Oct; 15(5):384-90. PubMed ID: 8536297
[TBL] [Abstract][Full Text] [Related]
16. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache.
Limmroth V; Biondi D; Pfeil J; Schwalen S
Headache; 2007 Jan; 47(1):13-21. PubMed ID: 17355489
[TBL] [Abstract][Full Text] [Related]
17. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of zonisamide in migraineurs with nonresponse to topiramate.
Chung JY; Kim MW; Kim M
Biomed Res Int; 2014; 2014():891348. PubMed ID: 25101297
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine.
Cernuda-Morollón E; Ramón C; Martínez-Camblor P; Serrano-Pertierra E; Larrosa D; Pascual J
Pain; 2015 May; 156(5):820-824. PubMed ID: 25735000
[TBL] [Abstract][Full Text] [Related]
20. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
Bellamy JL; Cady RK; Durham PL
Headache; 2006 Jan; 46(1):24-33. PubMed ID: 16412148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
